• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Cochrane Review: Do Omega-3 Fatty Acids Reduce Cardiovascular Disease? 

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • There have been studies in the literature suggesting that omega-3 polyunsaturated fats may be protective against cardiovascular disease although literature is conflicting  
    • Omega-3 fats are ingested in the form of oily fish or fish oil (often fish liver) capsules and can also be plant based  
      • Oily fish: long-chain omega-3 (LCn3), which includes eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)  
      • Plant based: Alpha-linolenic acid (ALA) 
    • There is professional guidance on this subject regarding the consumption of fish and some organizations also recommend supplementation for those with coronary artery disease (e.g., AHA) 
  • There may be bias in previous studies, because fish consumption in some regions is associated with a more health-conscientious life style  
  • Abdelhamid et al. (The Cochrane Library, 2018) sought to determine the impact of fish- and plant-based omega-3 on all-cause mortality, cardiovascular (CVD) events, adiposity and lipids 
    • Review commissioned by WHO to inform the next set of recommendations on polyunsaturated fatty acid intake in children and adults  

METHODS: 

  • Database search of RCTs and meta-analysis 
    • Studies lasting ≥12 months  
    • Intervention: Supplementation and/or advice to increase LCn3 or ALA (>10% of total fat) intake  
    • Control: Usual or lower intake  
  • To avoid bias, two independent researchers assessed studies for inclusion, extracted data and assessed validity  
  • Primary outcome: Long-chain omega-3 (LCn3, fish-based omega-3 fats) or ALA (plant-based omega-3 fats) fats and risk for 
    • All-cause mortality | Cardiovascular deaths | Cardiovascular events | Coronary heart disease deaths | Coronary heart disease events | Stroke | Arrhythmia | Adiposity and lipids 
  • Secondary Outcomes: If omega-3 fatty acids are found to be effective, is protection  
    • Seen in both low and at high risk for cardiovascular disease 
    • Dependent on dose and duration  
    • Different depending if dietary or supplemental 
  • GRADE methods used to assess result quality

RESULTS: 

  • 79 RCTs were included  
  • There was little or no effect of increasing LCn3 on 
    • All-cause mortality | Cardiovascular mortality | Cardiovascular events | CHD mortality | Stroke | Arrhythmia, CHD events 
  • Increasing ALA intake made little to no difference for 
    • All-cause mortality | Cardiovascular mortality | CHD events 
  • ALA enriched diet did reduce the risk of 
    • Cardiovascular events: Reduction from 4.8% to 4.7% – risk ratio (RR) 0.95; 95% CI, 0.83 to 1.07 (low-quality evidence) 
    • CHD mortality: Reduction from 1.1% to 1.0% – RR 0.95; 95% CI, 0.72 to 1.26 (moderate-quality evidence) 
    • Arrhythmia:Reduction from 3.3% to 2.6% – RR 0.79; 95% CI, 0.57 to 1.10 (moderate-quality evidence) 
    • Evidence for stroke unclear due to low-quality evidence

CONCLUSION: 

  • High-quality evidence demonstrated no benefit to EPA or DHA in the prevention of all-cause deaths and cardiovascular events 
  • Moderate-quality evidence suggests that there is likely little or no difference for cardiovascular death, coronary deaths or events, stroke, or heart irregularities 
  • Foods rich in omega-3 fats (such as walnuts, canola oil or enriched margarine)  
    • Likely makes little difference for all-cause or cardiovascular deaths or coronary events 
    • May protect against slightly reduce cardiovascular events, coronary mortality and heart irregularities

Learn More – Primary Sources: 

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

More Evidence on Whether Eating Nuts Is Associated with Cardiovascular Disease
How do Walnuts Improve Appetite and Glycemic Control?
Omega-3 PUFAs: Do They Really Work for the Treatment of Dementia?
PURE Study Results – Carbs vs Fat Intake to Reduce Cardiovascular Morbidity and Mortality?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site